Richard T. Silver, M.D.

Medical Oncology
Hematologic Malignancy
Richard Silver

Richard T. Silver, M.D. is Professor of Medicine, Attending Physician and Emeritus Director of the Richard T. SIlver M.D. Myleoproliferative Neoplasm Center at New York Presbyterian-Weill Cornell Medical Center. He is also Medical Director, The Cancer Research and Treatment Fund, Inc.; past President and current Member of the Board of Directors, New York State Society of Medical Oncologists and Hematologists; past President and currently Senior Advisor, Weill Cornell Medical College, Alumni Association, Life Member, Cornell University Council.

 

Dr. Silver received his M.D. from Cornell University Medical College. He completed an internship in medicine and a residency in medicine (hematology) at The New York Hospital Cornell Medical Center. He was a Clinical Associate in the Leukemia Service of the General Medicine Branch at the National Cancer Institute, National Institutes of Health. Afterwards, he served as a Visiting Fulbright Professor at the University of Bahia, Salvador, Brazil. He then returned to The New York -Weill Cornell Medical Center where he has remained.

 

Dr. Silver has combined a career of clinical investigation, teaching and practice. He draws patients from the large metropolitan New York City area and internationally. In his career, Dr. Silver has written more than  279  peer-reviewed articles, written or edited more than 4 books, more than 20 chapters, and 254 abstracts, and served on numerous review boards and study groups; belonged to over 13 medical societies; held 10 visiting professorships; delivered more than 200 invited national lectures and 50 international lectures. He has served as editor and reviewer of many medical journals and articles; He has been the principal investigator of numerous clinical trials; He served as Acting Chairman and Vice Chairman of Cancer and Leukemia Group B, a large multi-institutional cancer research group; in this group he served also as Chair of the Chronic Leukemia Subcommittee.  Dr. Silver is routinely listed among The Best Doctors in New York and is listed in Who's Who in America, Who's Who in the World, Who's Who in Science, etc.

 

His current interests are in developmental therapeutics and evaluating small molecular drugs for treating chronic myeloid leukemia and the myleoproliferative neoplasms, polycythemia vera, essential thrombocythemia and primary myelofibrosis.  He is currently the Principal Investigator at Weill Cornell Medical Center of the Myeloproliferative Research Consortium, an RO1 NIH grant on the treatment of myleoproliferative neoplasms, and served as Chairman of its Membership Committee and on its Executive Committee.  He is also Principal Investigator for Weill Cornell to the European LeukemiaNet.


A summary of Dr. Silver's Education, Training and/or Faculty Appointments follows:

 

Medical Training:

  • Resident in Medicine (Hematology), The New York Hospital-Cornell Medical Center, 1957-1958
  • Assistant Resident in Medicine, The New York-Cornell Medical Center, 1956-1957
  • Intern in Medicine, The New York Hospital-Cornell Medical Center, 1953-54
  • Clinical Associate, General Medicine Branch, National Cancer Institute, National Institutes of Health, 1954-1956
  • Visiting Fulbright Professor, University of Bahia, Salvador, Brazil, 1960-1961

 

Certification:

  • Diplomat, Medical Oncology, American Board of Internal Medicine, 1973
  • Fellow, American College of Physicians, 1965
  • Diplomat, American Board of Internal Medicine, 1962
  • Licensure, New York State, 1954
  • Diplomat, National Board of Medical Examiners, 1953

 

 

 

Current Appointments:

  • Professor of Medicine, Weill Cornell Medical
  • Attending Physician, New York-Presbyterian Hospital 
  • Emeritus Director, Richard T. SIlver M.D. Myleoproliferative Neoplasm Center, Weill Cornell Medical College
  • Medical Director, The Cancer Research and Treatment Fund, Inc. 
  • Board of Directors, New York State Society of Medical Oncologists and Hematologists 
  • Senior Advisor, Alumni Association, Weill Cornell Medical College
  • Life Member, Cornell University Council

 

Awards and Honors:

  • New York State Society of Medical Oncologists and Hematologists Award of Appreciation for Service as President 1991-2000
  • Richard T. Silver Distinguished Visiting Professorship,1998
  • Pasmantier Award of the New York Cancer Society and Fund for Blood and Cancer Research for Outstanding Accomplishment and Distinguished Service to Clinical Medicine and Medical Oncology, June 1999
  • Richard T. Silver Distinguished Professorship in Hematology & Medical Oncology at Weill Medical College of Cornell University, 2001
  • Timothy Gee Award for Outstanding Clinician, Teacher, Mentor, Humanist presented by Sass & Strauss Foundation, May 19, 2001
  • Lifetime achievement award for pioneering work in clinical hematology and as Founder and Medical Director of the Cancer Research & Treatment Fund (CR&T), 2008
  • Distinguished Emeritus member, American Society of Hematology, 2010
  • Lifetime of Academic Achievement, Dedication and Service to Weill Cornell Medical College (WCMC), 2011
  • The Weill Cornell Medical College Alumni Association Special Achievement Award, 2012
  • Lifetime Achievement Award, The SASS Foundation for Medical Research, Inc., 2012
  • Lifetime Achievement Award in the field of Hematology, Israel Society of Hematology and Blood Transfusion and the University of Texas MD Anderson Cancer Center, 2013
  • Dedication, Richard T. Silver, M.D. Myeloproliferative Neoplasm Center at Weill Cornell Medical College, New York, New York, Weill Cornell Medical College, 2014

 

 

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Health Republic
  • Medicaid
  • Medicare [Medicare]
  • Medicare
  • Oscar
  • POMCO
  • Rockefeller University - CoreSource

Publications

Books  

  1. Silver RT: Morphology of the blood and marrow in clinical practice. Grune and Stratton, Inc., New York, NY, 1970.
  2. Silver RT, Lauper RD, Jarowski CI: A synopsis of cancer chemotherapy.  Dun-Donnelley Publishing Corp., New York, 1977.
  3. Silver RT, Editor: Clinical Topics in Cancer: Diagnosis and Treatment, LeJacq Publishing Co., 1982.
  4. Silver RT and Tefferi A. Myeloproliferative Disorders. Silver RT and Tefferi A (eds). Informa Healthcare, New York, 2007.
  5. Silver RT: Polycythemia vera and other polycythemia syndromes.  In:  Ansell SM (ed):  Rare Hematological Malignancies.  Springer Science and Business Media LLC, 2008

 

Chapters

  1. Silver RT: Polycythemia. In: Difficult Problems in Internal Medicine, J.E. Barondess (Ed), Williams and Wilkins Press, 1971, pp. 442. 
  2. Coleman M, Silver RT: Chemotherapy of plasma cell myeloma and related disorders.  In: antibiotics and Chemotherapy, H.S. Grenzach, R.W. Brockman, F.E. Hahn (Eds), Basel W, Karger S: Vol. 18, Chapt. 4, 1973, pp. 103-106. 
  3. Silver RT: Leukemoid reactions.  In: Textbook of medicine, Beeson and McDermott (Eds), W.B. Saunders Co., Philadelphia, 1975, pp. 1484-85.
  4. Silver RT: Myeloproliferative disorders.  In: Textbook of Medicine, Beeson and McDermott (Eds), W.B. Saunders Co., Philadelphia, 1975, pp. 1497-98.
  5. Silver RT: Chronic lymphocytic leukemia: Proposed guidelines for protocol studies.  In: Cancer Therapy: Prognostic Factors and Criteria of Response. M.J. Staquet, Raven Press, New York, 1975.
  6. Silver RT: Treatment of the chronic leukemias.  In: Clinical Cancer Chemotherapy, E.M. Greenspan (Ed), Raven Press, New York, 1975. 
  7. Silver RT: The chronic leukemias.  In: Current Therapy, H.F. Conn (Ed), W.B. Saunders Co., 1976, pp. 311-316. 
  8. Pasmantier MW, Coleman M, Silver RT, Birnbaum SJ: Endometrial cervical and vulva cancer.  In: Randomized Trials in Cancer: A Critical Review by Sites, M.J. Staquet (Ed), Raven Press, 1978. 
  9. Silver RT, Lauper RD, Jarowski CI: Recent advances in cancer chemotherapy.  In: Cornell Medical Update, L.A. Wallis (Ed), Yorke Medical Books, Dun-Donnelley Publishing Corp., 1978, pp. 90-98. 
  10. Silver RT, Lauper RD, Jarowski CI: Compendium of antineoplastic agents.  In: Cornell Medical Update, L.A. Wallis (Ed), Yorke Medical Books, Dun-Donnelley Publishing Corp., 1978, pp. 99-135. 
  11. Silver RT: Leukemoid reactions, pp. 917; myeloproliferative disorders, pp. 943; Agnogenic myeloid metaplasia.  In: Cecil, Textbook of Medicine, J.D. Wyngaarden, L.H. Smith (Eds), W.B. Saunders Co., Philadelphia, 1982. 
  12. Silver RT, Lauper RD, Jarowski CI: A Synopsis of Cancer Chemotherapy.  Yorke Medical Books, 2nd edition, 1986. 
  13. Silver RT: The chronic leukemias.  In: Conn Current Therapy, R.E. Rakel (Ed), W.B. Saunders Company, 1986, pp. 330‑336. 
  14. Stenzel KH, Wang J, Walle A, Suthanthiran M, Silver RT, Novogrodsky A: Adoptive immunotherapy for renal adenocarcinoma: Use of oxidizing mitogen‑treated mononuclear leukocytes and continuous infusion of interleukin‑2.  In: Progress in Regional Cancer Therapy, R. Jakesz/H. Rainer (Eds), Springer‑Verlag, Berlin‑Heidelberg, 1990, pp. 304‑309. 
  15. Silver RT: Agnogenic myeloid metaplasia.  In: Current Diagnosis, Rex Conn (Ed), W.B. Saunders Co, 1991, pp. 581‑583.  
  16. Silver RT: Chronic myeloid leukemia.  In: Cancer Medicine, Third Edition, John Spahr, Jr. (Ed), Lea & Febiger, 1993, pp. 1934‑1942. 
  17. Silver RT: Chronic myeloid leukemia. In: Conn's Current Therapy, R.E. Rakel (Ed), W.B. Saunders Company, 1994, pp. 404-407. 
  18. Silver RT (Guest Editor): New approaches to the treatment of cancer-related anemia.  Monograph, Seminars in Oncology, 21(2)suppl.3:April, 1994. 
  19. Silver RT: Polycythemia Vera.  In: Conn's Current Therapy, R.E. Rakel (Ed), W.B. Saunders Company, 1995, pp. 387-389. 
  20. Silver RT: The anemia of malignancy; issues and treatment. Monograph, Publishers, Ortho Biotech, June, 1995. 
  21. Talpaz M. Giles F, Goldman JM, Silver RT, Tura S: Current perspective on the management of chronic myelogenous leukemia.   Monograph, (Proceedings of a Consensus Roundtable, 9/23/95, Washington, D.C.), Publishers, Scienta Healthcare Education, Sept. 1996. 
  22. Silver RT: The Myeloproliferative Disorders and their Treatment with interferon    Alfa. Molecular Biology of Hematopoiesis, 1996, pp.571-576. 
  23. Silver RT: Chronic myeloid leukemia. Cancer Medicine, 4th edition, Holland, Bast Morton, et al (Eds), Williams & Wilkins, 1997, pp. 2651-2661.
  24. Silver RT: Polycythemia Vera and Other Polycythemia Syndromes. Current Diagnosis, 9th Edition; W.B. Saunders Co., 1997. pp. 505-509. 
  25. Lichtin AE, Woolf SH, Silver RT, Hehlmann R. Chronic Myeloid Leukemia—ASH Practice Guideline and Beyond. American Society of Hematology Education Program Book,1998, pp. 433-453. 
  26. Silver RT:  Chronic Myeloid Leukemia: Practice Guidelines. Trends in Onco-Hematology, Volume 6, 60, December 1998.  Selected reports from the 40th annual meeting of  Miami, USA. 
  27. Silver RT: Chronic myeloid leukemia. Conn’s Current Therapy, 1999 Edition. Robert E. Rakel (Ed), W.B. Saunders Co., 1999, pp.426-428. 
  28. Silver RT:  Polycythemia. Saunders Manual of Medical Practice, Edition 2. Ed. R. E. Rakel (Eds), W. B. Saunders Co., 2000, pp. 797-799. 
  29. Carella AM, Daley GQ, Siler, RT, Goldman JM, Hehlmann R: Chronic Myeloid Leukemia-Biology and Treatment. Martin Dunitz Ltd., UK, 2001, pp. 225-237.
  30. Silver RT: Evidence-based guidelines for the treatment of chronic-phase chronic myeloid leukemia. Chronic Myeloid Leukemia, Carello, Daley, Eaves, Goldman & Hellmann (Eds), Martin Dunitz Ltd., 2001, pp. 225-237
  31. Silver RT:  Chronic Myeloid Leukemia.  Cancer Management: A Multidisciplinary Approach handbook, 6th edition, Jorge E. Cortes, Hagop Kantarjian (Eds), PPR, Inc., 2002, pp. 709-720
  32. Silver RT, Frei E: Chronic Myeloid Leukemia, Clinical Practice of Hematology and Oncology. B. Furie, P. Cassileth, M. Atkins, RJ. Mayer (Eds). W.B. Saunders Co., Philadelphia, PA, 2003, pp. 671.
  33. Silver RT: Chronic Myeloid Leukemia, Holland-Frei Cancer Medicinee.6, edited by: D. Kufe, R. Pollock, R. Weichselbaum, R. Bast, Jr., J. Holland and E. Frei, III, BC Decker Inc., Hamilton, London, 2003, pp. 2117.
  34. Cortes JE, Silver RT, and Kanarjian H: Chronic Myelogenous Leukemia. Cancer Management: A Multidisciplinary Approach, 9th edition, Pazdur R, Coia L, Hoskins WJ, and Wagman LD (Eds), CMP United Business Media, New York, NY, pp. 797-810, 2005. 
  35. Cortes J, Silver RT, Kantarjian H: Chronic Myeloid Leukemia. Holland-Frei Cancer Medicinee.7, D. Kufe, R. Pollock, R. Weichselbaum, R. Bast, Jr., J. Holland and E. Frei, III (Eds), Chapter 114, pp. 1761-1771,  BC Decker Inc., Hamilton, London, 2006.
  36. Cortes JE, Silver RT, and Kanarjian H: Chronic Myelogenous Leukemia. Cancer Management: A Multidisciplinary Approach. 10th edition, Pazdur R, Coia L, Hoskins WJ, and Wagman LD (Eds), CMP United Business Media, New York, 2006, Chapter 33, Section 34 pp. 1-11.
  37. Silver RT: Clinical Features and Making the Diagnosis. Chronic Myeloproliferative Diseases in Clinical Malignant Hematology, Sekeres M, Kalaycio ME, Bolwell BJ (Eds), McGraw Hill, 2007, pp 461-467.
  38. Cortes J, Silver RT, Kantarjian H: Chronic Myelogenous Leukemia. Cancer Management: A Multidisciplinary Approach, 10th edition, Pazdur R, Coia L, Hoskins WJ, and Wagman LD (Eds), CMP Healthcare Media, 2007 – 2008, pp. 789-804.
  39. Cortes J, Silver RT, Kantarjian H:  Chronic Myeloid Leukemia.  In:  Cancer Medicine 7 (eds) Holland-Frei; Kufe D, Pollock R, Weichselbaum R, Bast R; BC Decker Inc.  Hamilton, London, Chapter 114, pp. 1761-1771.
  40. Silver RT and Tefferi A. Biology and Management. In: Myeloproliferative Disorders. Silver RT and Tefferi (eds). Informa Healthcare, New York, 2007. 
  41. Sirhan S, Silver RT. Management of Polycythemia Vera. In: Myeloproliferative Disorders. Silver RT and Tefferi A (eds). Informa Healthcare, New York, 2007, p. 87.
  42. Silver RT. Polycythemia vera and other polycythemia syndromes. In: Rare Hematological Malignancies. Ansell SM (ed)Springer Science and Business Media LLC, 2008.
  43. Silver RT:  The Blast Phase of Chronic Myeloid Leukemia.  In:  Best Practice & Research Clinical Haematology.  2009.
  44. Cortes JE, Silver RT, and Kantarjian H:  Chronic myeloid leukemia.  In: Cancer Management:  A Multidisciplinary Approach. 2009.  pp.1-16.  11th Edition.
  45. Cortes JE, Silver RT, and Kantarjian H:  Chronic Leukemia – 30: Leukemia Central Desktop, CMHG Author, July 18, 2011. 

 

Articles

  1. Wells CE, Silver RT: The neurologic manifestations of the acute leukemias: a clinical study.  Pediatric Current in Nutrition and Medicine.  1957; 6:22.
  2. Wells CE, Silver RT: The neurologic manifestations of the acute leukemias: a clinical study.  Ann Int Med.  1957 Mar; 46(3):439-49.
  3. Silver RT, Beal G, Schneiderman H, McCullough NB: The role of the mature neutrophil in bacterial infections in acute leukemia.  Blood.  1957 Sep; 12(9):814-21.
  4. Silver RT, Utz J, Frei E, McCollough N: Fever, infection and host resistance in acute leukemia.  Am J Med 1958 Jan; 24(1):25-39.
  5. Watkin D, Silver RT: Nitrogen, mineral, uric acid and basal metabolism in a case of adult acute leukemia with extensive osteolytic bone disease.  Am J Med.  1958 Apr; 24(4):638-47.
  6. Frei E, Holland J, Schneiderman M, Pinkel D, Selkirk G, Freireich E, Silver RT, Gol L, Regelson W: A comparative study of the regimens of combination chemotherapy in acute leukemia.  Blood.  1958 Dec; 13(12):1126-48.
  7. Ellison RR, Silver RT, Engle RL Jr: Comparative study of 6-chloropurine and 6-mercaptopurine in acute leukemia in adults.  Ann Intern Med.  1959 Aug; 51:322-38.
  8. Silver RT: Sojourn in Brazil, Cornell Alumni Bulletin, 1959.
  9. Silver RT, Utz J, Fahey J, Frei E: The nature of the antibody response in acute leukemia.  J Lab & Clin Med.  1960; 56:634.
  10. Silver RT, Kellner A, Haber J: Evidence for a new allele in the Kidd blood group system.  Nature.  1960 May 7; 186:481.
  11. Silver RT, Pedreira L, Korngold L, Engle RL: Studies of the serum protein abnormalities in kala azar.  Proc Soc for Experimental Biol and Med.  1961; 106:365.
  12. Silver RT, Utz J, Fahey J, Frei E: The nature of the antibody response in acute leukemia.  Modern Med.  1961; 29:100.
  13. Silver RT: Medical adventures in the Upper Xingu. Cornell University Medical College Alumni Bulletin.  Winter 1968; pp. 3-8.  Also: Bibl Haematol.  1962; 13:167-9.
  14. Silver RT, Haber J, Kellner A: Blood group studies of jungle Indians of Mato Grosso.  Transfusion.  1962 Mar-Apr; 2:110-4.
  15. Pedreira L, Engle RL, Silver RT: Studies of the plasma proteins in pregnancy using starch zone electrophoresis.  Clin Chim Acta.  1962 Sep; 7:710-3.
  16. Silver RT:  Infection, fever and host resistance in neoplastic diseases. J Chron Dis.  1963 Jul; 16:677-701.
  17. Silver RT, Jenkins D, Engle RL: Use of testosterone and busulfan in the treatment of myelofibrosis with myeloid metaplasia.  Blood.  1964 Mar; 23:341-353.
  18. Silver RT: Bone marrow aspiration and biopsy.  GP.  1965 Mar; 31:100-6.
  19. Silver RT: Bone marrow biopsy.  Medical Digest.  1966; 825:50.
  20. Nachman RL, Horowitz HL, Silver RT: Platelet amino acids in essential thrombocytosis. Blood.  1966 May; 27(5):715-21.
  21. Karanas A, Silver RT: Natural history of the terminal phase of chronic granulocytic leukemia. Proc Amer Assoc Cancer Res.  1966; 7:65.
  22. Silver RT, Keuhnelian J, Jenkins DE Jr, Engle RL Jr, Marshall VF: Influence of testosterone on the development of bone marrow at sites of transplanted bladder mucosa.  Invest Urol.  1967 Jan; 4(4):314-20.
  23. Kyle RA, Carbone PP, Lynch JJ, Owens AH, Costa G, Silver RT, Cuttner J, et al: Evaluation of tryptophan mustard in patients with plasmacytic myeloma.  Cancer Res.  1967 Mar; 27(3):510-5.
  24. Carbone PP, Spurr C, Silver RT, et al: Management of patients with malignant lymphoma.  A comparative study with cyclophosphamide and vinca alkaloids.  Cancer Res.  1968; 28:811.
  25. Webb DI, Silver RT: Hodgkin's disease: Value of bone marrow biopsy.  N Engl J Med.  1968 Jul 4; 279(1):46.
  26. Karanas A, Silver RT: Characteristics of the terminal phase of chronic granulocytic leukemia.  Blood.  1968 Sep; 32(3):445-59.
  27. Ellison RR, Holland JF, Weil M, Silver RT, et al: Arabinoside cytosine: a useful agent in the treatment of acute leukemia in adults.  Blood.  1968 Oct; 32(4):507-23.
  28. Levin WC, Griffith K, Huguley CM, Silver RT, Karanas A, et al: Proposed guidelines for protocol studies: Chronic lymphocytic leukemia.  Cancer Chemotherapy Report.  1968; 1:41.
  29. Hoogstraten B, Silver RT, et al: Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma.  Blood.  1969; 33:370.
  30. Silver RT: Treatment of chronic lymphocytic leukemia. Sem in Hematol.  1969 Oct; 6(4):344-56.
  31. Webb DI, Ubogy G, Silver RT: Importance of bone marrow biopsy in the clinical staging of Hodgkin's disease.  Cancer.  1970 Aug; 26(2):313-7.
  32. Fratantoni JC, Silver RT: Autoimmune hemolytic anemia and Gaucher cells.  Proc Amer Soc Hematol.  1970; 13:312.
  33. Ohnuma T, Rosner R, Levy RN, Cuttner J, Moon JH, Silver RT, et al: Treatment of adult leukemia with L-asparaginase (NSC-109229).  Cancer Chemotherapy Rep.  1971 Jun; 55(3):269-75.
  34. Silver RT: Ineffectiveness of fluoride therapy in multiple myeloma. A CALGB study.   N Engl J Med.  1972; 285:1283.
  35. Ellison RR, Hoogstraten B, Holland JF, Silver RT, et al: Intermittent therapy with 6-mercaptopurine (NSC-755) and methotrexate (NSC-740) given intravenously to adults with acute leukemia.  Cancer Chemotherapy Rep, part I.  1972 Aug; 56(4):535-42.
  36. Well M, Glidewell OJ, Jacquilat C, Levy R, Silver RT, et al: Daunorubicin in the therapy of acute granulocytic leukemia.  Cancer Res.  1973 May; 33(5):921-8.
  37. Kyle RA, Costa G, Cooper MR, Ogawa M, Silver RT, et al: Evaluation of aniline mustard in patients with multiple myeloma.  Cancer Research.  1973 May; 33(5):956-60.
  38. Smith J, Pasmantier M, Silver RT, et al: Selective versus routine laparotomy in the staging of Hodgkin's disease.  JAMA.  1973 May 14; 224(7):1026-8.
  39. Vinciguerra V, Silver RT: The importance of bone marrow biopsy in the staging of patients with lymphosarcoma.  Blood.  1973 Jun; 41(6):913-20.
  40. Cucin RL, Coleman M, Eckardt JJ, Silver RT: The diagnosis of miliary tuberculosis: utility of peripheral blood abnormalities, bone marrow and liver needle biopsy.  J Chron Dis.  1973 Jun; 26(6):335-61.
  41. Silver RT, Nisce L, Hoogstraten B, et al:  Combination chemotherapy-radiotherapy for stage III Hodgkin's disease. A CALGB study.  Arch Int Med.  1973; 131:424I.
  42. Costa G, Engle RL, Schilling A, Silver RT, et al: Melphalan and prednisone: An effective combination for the treatment of multiple myeloma.  A CALGB study.  Am J Med.  1973; 54:589.
  43. Silver RT, Stutzman L, Glidewell O, et al: Multiple chemotherapeutic agents for Hodgkin's disease.  A CALGB study.  JAMA.  1973; 225:1202.
  44. Coleman M, Silver RT.  The chemotherapy of plasma cell myeloma and related disorders.  Antibiot Chemother.  1974; 18:112-47. 
  45. Sharer LR, Barondess JA, Silver RT, Gray GF:  Association of Hodgkin's disease and Gaucher's disease.  Arch Pathol.  1974 Dec; 98(6):376-8.
  46.  Pasmantier MW, Coleman M, Silver RT.  Diagnosis of plasma cell myeloma.  Am Fam Physician.  1975 Jan; 11(1):76-81.
  47. Drout D, Moore A, Rothman H, Silver RT, Eisnmenger W: Acute hemolytic episodes 37 years apart.  N Engl J Med.  1975 Jan 23; 292(4):213.
  48. Kyle RA, Seligman BR, Wallace HJ Jr, Silver RT, Glidewell O, Holland JF.  Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208).  Cancer Chemother Rep.  1975 May-Jun; 59(3):557-62.
  49. Ellis JT, Silver RT, Coleman, Geller SA: The bone marrow in polycythemia vera.  Sem in Hematol.  1975 Oct; 12(4):433-44.
  50. Cuttner J, Wasserman LR, Martz G, Sonntag RW, Kyle RA, Silver RT, et al: The use of low-dose prednisone and melphalan in the treatment of poor risk patients with multiple myeloma.  Med and Ped Oncol.  1975; 1(3):207-16.
  51. Carey RW, Ribas-Mundo M, Ellison RR, Glidewell O, Lee ST, Cuttner J, Levy RN, Silver RT, et al:  Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.  Cancer.  1975; 36:1560.
  52. Silver RT, Coleman M: Chronic leukemia in adults.  Continuing Education for the Family Physician.  1976; 4:28-35.
  53. Pasmantier MW, Coleman M, Silver RT: Chemotherapy of non-Hodgkin's lymphoma.  Med Clin North Am.  1976 Sep; 60(5):1043-1052.
  54. Coleman M, Lightdale CJ, Vinciguerra VP, Degnan TJ, Goldstone MJ, Horowitz ST, Winawer SJ, Silver RT: Peritoneoscopy in Hodgkin's disease: Confirmation of results by laparotomy.  JAMA.  1976; 236:2634-2636.
  55. Sawitsky A, Rai KR, Aral I, Silver RT, et al: Mediastinal irradiation for chronic lymphocytic leukemia.  Am J Med.  1976 Dec; 61(6):892-6.
  56. Vinciguerra V, Coleman M, Jarowski CI, Degnan TJ, Silver RT: A new combination chemotherapy for resistant Hodgkin's disease.  JAMA.  1977; 237:33-35.
  57. Pasmantier MW, Coleman M, Silver RT: Value of biopsy in diagnosis of primary lymphosarcoma of marrow.  Arch Int Med.  1977; 137:52-54.
  58. Fialk MA, Coleman M, Grant MD, Pasmantier MW, Silver RT: Case report: Splenectomy in patients with Hodgkin's disease and marrow hypoplasia. Am J Med Sci.  1977 Jul-Aug; 274(1):87-91.
  59. Silver RT, Young RC, Holland JF: Some new aspects of modern cancer chemotherapy. Am J Med.  1977 Nov; 63(5):772-87.
  60. Turman S, Coleman M, Silver RT, Pasmantier M: High dose methotrexate with citrovorum factor in adult resistant lymphoma.  Cancer.  1977; 40:2823.
  61. Pasmantier MW, Coleman M, Kennedy BJ, Eagan R, Carolla R, Weiss R, Leone L, Silver RT: Piperazinedione in metastatic renal carcinoma.  Cancer Treatment Rep.  1977; 61:1731.
  62. Pasmantier MW, Coleman M, Silver RT, Birnbaum SJ: Endometrial, cervical and vulva cancer.  Randomized trials in cancer: A critical review by sites edited by Maurice J. Staquet, Raven Press, NY, 1977.
  63. Sawitsky A, Rai KR, Glidewell O, Silver RT: Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. A CALGB study.  Blood.  1977 Dec; 50(6):1049-59.
  64. Jarowski CI, Fialk MA, Murray HW, Gottlieb GJ, Coleman M, Steinberg CR, Silver RT: Fever, rash and muscle tenderness: A distinctive clinical presentation of disseminated candidiasis.  Arch Int Med.  1978; 138:544-6.
  65. Maurice P, Glidewell O, Jacquillat C, silver RT, Et al: Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.  Cancer.  1978 May; 41(5):1658-63.
  66. Brogadir S, Fialk MA, Coleman M, Vinciguerra V, Degnan T, Pasmantier M, Silver RT: Morbidity of staging laparotomy in Hodgkin's disease.  Am J Med.  1978; 64:429-33.
  67. Wolf DJ, Silver RT, Coleman M: Factors associated with prolonged survival in chronic myeloid leukemia.  Cancer.  1978 Oct; 42(4):1957-63.
  68. Wolf DJ, Silver RT, Coleman M: Splenectomy in chronic myeloid leukemia: A review.  Ann Intern Med.  1978 Nov; 89(5 Pt1):684-9.
  69. Silver RT, Sawitsky A, Rai K, Holland JF, Glidewell O:  Guidelines for protocol studies in chronic lymphocytic leukemia.  A CALGB study.  Am J Hematol.  1978; 4:343-58.
  70. Sawitsky A, Rai K, Silver R: Mediastinal irradiation for chronic lymphocytic leukemia.  In: Yearbook of Medicine, Edited by David E. Rogers, M.D., et al. 1978; pp 237.
  71. Henderson ES, Scharlau C, Cooper MR, Haurani FI, Silver RT, et al.  Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113.  Leuk Res.  1979; 3(6):395-407.
  72. Hayes DM, Pajak TF, Rege V, Silver RT, et al: Combination chemotherapy for non-Hodgkin's lymphomas: A ten year follow-up CALGB study.  Med & Ped.  1979; 6:23-38.
  73. Rowley JD, Resnick GD, Whitman SL, Senterfit L, Silver RT: Variant Ph1 translocation in chronic myeloid leukemia.  Blood.  1979; 54:294.
  74. Wiernik PH, Glidewell O, Silver RT: A comparative trial of daunorubicin, cytosine arabinoside and thioquanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.  Med & Ped Oncol.  1979; 6:261-77.
  75. Pinkel D, Silver RT, Simone JV, Van Eys J: Exploring current leukemia therapies.  Patient Care.  1979; 13:54-78.
  76. Coleman M, Silver RT, Pajak TF, et al: Combination chemotherapy for terminal-phase chronic granulocytic leukemia: CALGB studies.  Blood.  1980; 55:22-36.
  77. Silver RT: The dying patient: A clinician's view.  Am J Med.  1980; 68:374-75.
  78. Silver RT: The Dying Patient.  Cornell Alumni News: 1980; pgs. 27-29.
  79. Wolf DJ, Silver RT, Coleman M: Waldenstron's macroglobullinemia – a review. The Medical Journal of the New York Hospital-Cornell Medical Center 1980; 1:24-30.
  80. Nissen NI, Pajak TF, Leone LA, Bloomfield CD, Silver RT, et al: Clinical trial of VP 16-213 i.v. twice weekly in advanced neoplastic disease.  A CALGB study.  Cancer.  1980; 45:232-35.
  81. Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, et al.  A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease.  Cancer.  1980 Aug 15; 46(4):654-62.
  82. Donavan PB, Landaw SA, Cresch C, Silver RT, et al: Resistance to therapy of acute leukemia developing in the course of polycythemia vera.  Nouv Rev Fr Hematol.  1981; 23(4):187-192.
  83. Brandstetter RD, Silver RT, Verma TK: Multiple (five) primary malignancies in one patient.  Southern Med J.  1981; 74(5):641-42.
  84. Rai K, Holland J, Glidewell O, Weinberg V, Brunner, Silver RT, et al: Treatment of acute myelocytic leukemia.  A CALGB study.  Blood.  1981; 58(6):1203-12.
  85. Laurence J, Coleman M, Allen S, Silver RT, Pasmantier M: Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.  Ann Int Med.  1982; 97:190-195.
  86. Pelus L, Saletan S, Silver RT, Moore M: Expression of IA antigens on normal and chronic myeloid leukemic human granulocyte-macrophage colony-forming cells (CFU-GM) is associated with the regulation of cell proliferation by prostaglandin E.  Blood.  1982; 59(2):284-92.
  87. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Silver RT, et al: Cytostine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study.  Blood.  1982; 60(2):454-62.
  88. Cornwell GG III, Pajak TF, Kochwa S, McIntyre OR, Glowienka LP, Brunner K, Rafla S, Silver RT, et al: Comparison of oral melphan, CCNU and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma.  A CALGB study.  Cancer.  1982; 50:1669-1675.
  89. Hollister D Jr, Silver RT, Gordon B, ColemanM: Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma.  Cancer.  1982; 50:1690-94.
  90. Tormey DC, Weinberg VE, Holland JF, Weiss RB, Glidewell OJ, Perloff M, Falkson G, Falkson HC, Henry PH, Leone LA, Fafla S, Ginsberg SA, Silver RT, et al: A randomized trial of five and three-drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.  A CALGB study.  J Clin Oncol.  1983; 1(2):138-45.
  91. Silver RT, Douglas RG: Endocytosis by the mononuclear phagocyte system and antoimmune disease.  Amer J Med.  1983; 74:481-93.
  92. Silver RT, Douglas RG, editors: Combined clinical basic science seminar: Nutrition and cancer by Dr. Rivlin.  Amer J Med.  1983; 75:843-54.
  93. Paciucci PA Ohnuma T, Cuttner J, Silver RT, Holland JF: Mitoxantrone in acute lymphoblastic leukemia.  Cancer Treatment Reviews.  1983; 10(B):65-68.
  94. Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF: Mitoxantrone in patients with acute leukemia in relapse.  Cancer Res.  1983; 43:3919-22.
  95. Pasmantier MW, Coleman M, Silver RT, et al: Administration of a complex chemotherapy regimen: Inpatient versus outpatient treatment.  Med & Ped Oncol.  1983; 11:333-35.
  96. Green M, Horton C, Spaulding M, Silver RT, Berenberg J, Kennedy BJ, Pajak TF, Comis R.  Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study.  J Clin Oncol.  1983 Sep; 1(9):559-65.
  97. Brower MS, Coleman M, Pasmantier MW, Silver RT, et al: Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin and cis-platinum (HAC): Results in both untreated and previously treated patients.  Med & Ped Oncol.  1984; 12:17-24.
  98. Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, Kennedy BJ, Cortes E, Silver RT, et al: A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer: A CALGB study.  Amer J Clin Oncol.  Cancer Clinical Trials.  1984; 7:231-39.
  99. Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Fafla S, Cuttner J, Silver RT, et al: Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: A prospective randomized trial by CALGB.  Blood.  1984; 64(1):267-74.
  100. Landesman R, Silver RT: Cytoreductive surgery.  Obst & Gyn (Letter).  1984; 64(1):148-49.
  101. Arlin ZA, Silver RT, et al: Phase I-II trial of mitooxantrone in acute leukemia.  Cancer Treatment Reports.  1985; 69(1):61-64.
  102. Chemitiganti S, Verma RS, Silver RT, Coleman M, Dosik H: Unusual translocations involving chromosomes 12;22 and 9;12 in a case of chronic myelogenous leukemia.  Cancer Genetics and Cytogenetics.  1985; 14:61-65.
  103. Henderson IC, Wolff S, Allegra J, Silver RT, et al: A randomized trial of novantrone versus adriamycin for metastatic breast cancer.  Advances in Cancer Chemotherapy, The Current Status of Novantrone, 1985.
  104. Henderson IC, Wolff SN, Allegra JC, Woodcock T, Silver RT, et al: A randomized trial comparing mitoxantrone and doxorubicin inpatients with metastatic breast cancer.  Advances in Cancer Chemoatherapy, The Current Status of Novantrone, 1985; pgs. 45-53.
  105. Gams RA, Keller J, Case DC Jr., Jones SE, Stein RS, Stuart JJ, Silver RT, et al: Novantrone in malignant lymphoma.  Advances in Cancer Chemotherapy, The Current Status of Novantrone.  1985; pgs. 75-77.
  106. Arlin ZA, Silver RT, et al: Further evaluation of mitoxantrone in acute leukemia.  Advances in Cancer Chemotherapy. The Current Status of Novantrone.  1985; pp. 91-94.
  107. Pasmantier MW, Coleman M, Silver RT, Mamaril AP, Quiguyan CC, Galindo A Jr.  Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients.  Cancer Treat Rep.  1985 May; 69(5):539-42.
  108. Silver RT, Case D, Jones S, Gams R, et al:  Novantrone mitoxantrone in the treatment of non-Hodgkin's lymphoma.  (Lederle Cooperative Group) Proc 14th Internat Congress of Chemotherapy.  1985 June; pgs. 23-28.
  109. Mayer RJ, Schiffer CA, Peterson BA, Silver RT, et al: Intensive postremission therapy in adults with acute nonlymphocytic leukemia with Ara-C by continuous infusion or bolus administration: preliminary results of a CALGB Phase I Study.  Sem in Oncol.  1985; 12(2), suppl 3:84-90.
  110. Wood WC, Weiss RB, Tormey DC, Holland JF, Henry PH, Leone LA, Fafla S, Silver RT, et al: A randomized trial of CMF vs. CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB study.  World J Surg.  1985; 9(5):714-18.
  111. Pasmantier MW, Coleman M, Silver RT, Ballard PW: Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, 5-FU; CHAMP-5) for ovarian carcinoma: Alternating sequences of combination regimens.  Cancer Treatment Rep.  1985; 69:689-93.
  112. Arlin Z, Silver RT, Cassileth P, Armentrout S, Gams R, et al:  Phase I-11 Trial of mitoxantrone in acute leukemia: An interim report.  Investigational New Drugs.  1985; 2:213-17.
  113. Coleman M, Pasmantier MW, Silver RT: Hac-cytoxan chemotherapy for ovarian carcinoma.  Alternating chemotherapy with intensification.  Cancer.  1985; 55:40-45.
  114. Silver, RT: Refractory Anemias, Pre‑Leukemia and Myelodysplasias.  Rev. Hosp. Clin. Fac. Med. S. Paulo.  1985; 40(6):266‑269.
  115. Verma RS, Thomas S, Coleman M, Silver RT, Dosik H: Position of the Y‑Chromosome at somatic metaphase in patients with chronic myelogenous leukemia (CML).  Experientia.  1986; 42(4):440‑41.
  116. Silver RT, Gale RP:  Chronic Myeloid Leukemia.  Amer. J. Med. 1986; 80 (6):1137‑48.
  117. Verma RS, Rodriquez J, Babu A, Chemitiganti S, Coleman M, Silver RT, Dosik H: Role of heterochromatin during preferential 9q;22q translocation in chronic myelogenous leukemia. Canadian Journal of Genetics and Cytology.  1986; 28(6): 998‑1002.
  118. Verma RS, Thomas S, Coleman M, Silver RT, Dosik H.  Length polymorphisms of the human Y chromosome in patients with chronic myelogenous leukemia.  Cancer Genet Cytogenet.  1987 Feb; 24(2):295-7.
  119. Coleman M, Gerstein G, Topilow A, Lebowicz J, Bernhardt B, Chiarieri D, Silver RT, Pasmantier MW: Advances in chemotherapy for large cell lymphoma.  Seminars in Hematology.  1987; 24:8‑20 (Suppl).
  120. Mayer RJ, Schiffer CA, Peterson BA, Budman DR, Silver RT, et al: Intensive Postremission Therapy in Adults With Acute Nonlymphocytic Leukemia Using Various Dose Schedules of ara‑C: A Progress Report from the CALGB.  Seminars in Oncology.  1987; 14(2):25‑31.
  121. Silver RT, Mick R, Cooper R, et al: A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of Cancer and Leukemia Group B.  Cancer.  1987; 60:1442‑48.
  122. Benn P, Soper L, Eisenberg A, Silver RT, Coleman M, Cacciapaglia B, Bennett L, Baird M, Silverstein M, Berger C, Bernhardt B: Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia.  Cancer Genet Cytogenet. 1987; 29(1):1‑7.
  123. Wang J, Walle A, Gordon B, Novogrodsky A, Suthanthiran M, Rubin A, Morrison H, Silver RT, Stenzel KH:  Adoptive immunotherapy for stage IV renal cell carcinoma:A novel protocol utilizing periodate and interleukin‑e‑activated autologous leukocytes and continuous infusions of low‑dose interleukin‑2.  Amer Jour Med.  1987; 83(6):1016‑23.
  124. Silver RT, Mick R, Degnan TJ, Holland JF, Cavelli F: Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis‑chloronitrosurea during the course of busulfan‑ maintained remission.  Cancer Investigation.  1988; 6(3):253‑60.
  125. Shustik C, Mick R, Silver RT, Sawitsky A, Rai K, Shapiro L: Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hemat. Onc.  1988, 6:7‑12.
  126. Coleman M, Armitage JO, Gaynor M, McDermott D, Weisenburger DD, Adler K, Beshevkin M, Silver RT, Reisman AM, Pasmantier MW: The COP‑BLAM programs: Evolving chemotherapy concepts in large cell lymphoma.  Seminars in Hematology.  1988; 25(2):23‑33.
  127. Soper L, Bernhardt B, Eisenberg A, Cacciapaglia B, Bennett L, Sanda A, Baird M, Silver R, Benn P: Clonal immunoglobulin gene rearrangements in chronic lymphocytic leukemia: A correlative study.  Am J Hem.  1988; 27:257‑64.
  128. Verma RS, Thomas S, Coleman M, Silver RT: Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML).  In J Cancer.  1988; 41:829‑31.
  129. Silver RT: Recombinant interferon‑alpha for treatment of polycythemia vera.  Lancet (Letter to the Editor).  1988; 13:403.
  130. Benn PA, Eisenberg A, Soper LA, Weinstein M, Silver RT, et al: Rearrangement of the breakpoint cluster region (bcr) of chromosome 22 as a diagnostic marker for chronic myeloid leukemia.  J Tumor Marker Onc.  1988; 3(1):101‑5.
  131. Botti AC, Silver RT, Macera MJ, Benn P, Verma RS: A new translocation involving chromosomes 8 and 9 in a Philadelphia‑negative chronic myelogenous leukemia.  Cancer Genet Cytogene.  1988; 35:51‑54.
  132. Verma RS, Macera MJ, Silver RT, Coleman M: Origin of near‑haploidy in malignant hematopoietic cells.  Leukemia Research.  1988; 12:941‑50.
  133. Weinstein ME, Grossman A, Perle MA, Wilmot L, Verma RS, Silver RT, Arlin Z, Allen SL, Amorosi E, Waintraub SE, Shapiro LR, Benn PA: The karyotype of Philadelphia chromosome‑negative, bcr rearrangement‑positive chronic myeloid leukemia.  Cancer Genet Cytogenet.  1988; 35:223‑29.
  134. Eisenberg A, Silver R, Soper L, Arlin Z, Coleman M, Bernhardt B, Benn P: The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.  Leukemia.  1988; 2:642‑47.
  135. Benn PA, Soper LA, Eisenberg A, Silver R, Bernhardt B: Use of immunoglobulin gene rearrangement to stage disease severity in chronic lymphocytic leukemia.  J Tumor Marker Oncology.  1988; 3:93‑99.
  136. Wang JCL, Walle A, Novogrodsky A, Suthanthiran M, Silver RT, Bander NH, Rubin AL, Stenzel KH: A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen‑activated autologous leukocytes and continuous infusion interleukin‑2.  J Clin Oncol.  1989; 7:1885‑91.
  137. Gilbert HS, Silver RT: Intron A (interferon alfa‑2b, recombinant) in the management of myeloproliferative disorders.  Monograph #11, Publishers‑Schering‑Plough International, September, 1989.
  138. Grossman A, Silver RT, Arlin Z, Coleman M, Camposano E, Gascon P, Benn PA.  Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.  Am J Hum Genet.  1989 Nov; 45(5):729-38.
  139. Stenzel KH, Wang J, Walle M, Suthanthiram M, Silver RT and Novogrodsky A: Adoptive immunotherapy for renal adenocarcinoma:  Use of oxidizing mitogen-treated mononuclear leukocytes and continuous infusion of interleukin-2. Progress In Regional Cancer Therapy.  1990; 304-9.
  140. Silver RT, Benn P, Verma RS, Coleman M, Soper L, Gutfriend A: Recombinant gamma‑interferon has activity in chronic myeloid leukemia.  Am J Clin Oncol.  1990; 13:49‑54.
  141. Silver RT: Chronic myeloid leukemia: A perspective of the clinical and biologic issues of the chronic phase.  Hematol/Oncol Clin NA.  1990; 4:319‑35.
  142. Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman E, Cherin E, Henderson ES, Weiss RB, Cooper MR, Silver RT, Leone L, Canellos GP, Gottlieb A, Holland JC: Quality of life assessment of Hodgkin's disease survivors: A model for cooperative clinical trials.  Oncology.  1990; 4(5):93‑101.
  143. Silver RT: Interferon in the treatment of myeloproliferative diseases. Sem in Hematol.  1990; 27(3):6‑14.
  144. Silver RT: A new treatment for polycythemia vera: recombinant interferon alfa.  Blood.  (Rapid Communication).  1990; 76(4):664‑65.
  145. Arlin ZA, Silver RT, Bennett JM: Blastic phase of chronic myeloid leukemia (blCML): A proposal for standardization of diagnostic and response criteria.  Leukemia.  1990; 4:755‑57.
  146. Budman DR, Korzun AH, Aisner J, Younger J, Silver R, Costanza M, Rice MA, Wood W:  A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group:CALGB 8443.  Cancer Invest.  1990; 8(6):571‑75.
  147. Silver RT, Case DC Jr, Wheeler RH, Miller TP, Stein RS, Stuart JJ, Peterson BA, Rivkin SE, Golomb HM, Costanzi JJ, Erslev AJ, Reisman A, Dugan M: Multicenter clinical trial of mitoxantrone in non‑Hodgkin's lymphoma and Hodgkin's disease.  JCO.  1991; 9:754‑61.
  148. Silver RT: Recombinant interferon alpha in the treatment of polycythemia vera. Blood. 1991; 77:2790‑91.
  149. Grossman A, Silver RT, et al: Densitometric analysis of southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia.  Leukemia.  1991; 5(7):540-47.
  150. Puccio CA, Mittelman A, Lichtman SM, Silver RT, Budman DR, Ahmed T, Feldman EJ, Coleman M, Arnold PM, Arlin ZA, Chun HG:  A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.  JCO.  1991; 9:1562‑69.
  151. Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woliver T, Royston I, Davey FR, Glicksman AS, et al: The effects of post induction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: A prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol.  1991; 9(11):2002‑15.
  152. Silverstein MN, Petitt RM, Solberg LA, Jr, Rosenblum B, Silver RT, et al: Anagrelide ‑ A therapy for thrombocythemic states: Experience in 577 patients.  Anagrelide Study Group.  AJM.  1992; 92:69‑76.
  153. Silver RT: Chronic myeloid leukemia. Current Opinion in Oncology.  1992; 4:66‑72.
  154. Silver RT, Karanas A, Dear KB, Weil M, Brunner K, Haurani F, Holland JF: Attempted Prevention of Blast Crisis in Chronic Myeloid Leukemia by the Use of Pulsed Doses of Cytarabine and Lomustine.  Leukemia & Lymphoma.  1992; 7:63‑68.
  155. Kaufmann T, Nisce LZ, Silver RT: Lymphomatoid papulosis: Case report of a patient managed with radiation therapy and review of the literature.  Am J Clin Oncol.  1992; 15(5):412‑16.
  156. Janov AJ, Anderson J, Cella DF, Zuckerman E, Kornblith AB, Holland JC, Kantor AF, Li FP, Silver RT, et al: Pregnancy outcome in survivors of advanced Hodgkin's disease.  Cancer.  1992; 70(3):688‑92.
  157. Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman MA, Cherin E, Henderson E, Weiss RB, Cooper MR, Silver RT, Leone L, Canellos GP, Gottlieb A, Holland JC: Hodgkin's disease survivors at increased risk for problems in psychosocial adaptation.  Cancer.  1992; 70(8):2214‑24.
  158. Christodoulidou F, Silver RT, Macera MJ, Verma RS: Disappearance of a highly unusual clone, 46,XY,del(7)(p12),t(9;22)(q34;q11), in chronic myeloid leukemia after treatment with recombinant interferon and cytosine arabinoside.  Cancer Genet Cytogenet.  1992; 64:174‑77.
  159. Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G, Hoffman R: Identification of BCR/ABL ‑ negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.  Blood.  1993; 81(3):801‑07.
  160. Case DC Jr., Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols R, Salmon SE, Silver RT, et al: Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.  JNCI.  1993; 85(10):801‑06.
  161. Silver RT: Interferon‑a2b: A new treatment for polycythemia vera.  Ann intern Med.  1993; 119(11):1091‑92.
  162. Sandler DP, Shore DL, Anderson JR, Davey FR, Arthur D, Mayer RJ, Silver RT, Weiss RB, Moore JO, Schiffer CA, Wurster‑Hill DH, McIntyre OR, Bloomfield CD: Cigarette smoking and risk of acute leukemia: Associations with morphology and cytogenetic abnormalities in bone marrow.  JNCI.  1993; 85(24):1994‑2003.
  163. Christodoulidou F, Silver RT, Macera MJ and Verma RS: Unusual Clonal Evolution During Blast Crisis of Chronic Myeloid Leukemia.  European Journal of Cancer.  1994; 30A(7): p. 1041.
  164. Ozer H, Anderson JR, Peterson BA, Budman DR, Cooper R., Kennedy BJ, Silver RT, Henderson ES, Duggan DB, Barcos M, Bloomfield CD, Gottlieb AJ:  Combination trial of subcutaneous recombinant 2b interferon and oral cyclophosphamide in follicular low‑grade non‑Hodgkin's lymphoma.  Med & Ped Oncol.  1994; 22:228‑35.
  165. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, Mayer RJ, Ball ED, Wurster-Hill D, Bloodfield CD, Liu ET: Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.  Blood.  1994; 83(6):1603-11.
  166. Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, Silver RT, et al: Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: A Cancer and Leukemia Group B study.  Can Chemo Pharmacol.  1995; 36:425-30.
  167. Rai KR, Davey F, Peterson B, Schiffer C, Silver RT, et al:  Recombinant alpha-2b-interferon in therapy of previously untreated hairy-cell leukemia: long term follow-up results of study by Cancer & Leukemia Group B.  Leukemia.  1995; 9(7):1116-20.
  168. Silver RT: Hydroxyurea and sickle cell crisis.  N Eng J Med.  (Letter to the Editor).  1995; 333(15):1008-09.
  169. Abdelaal AF, Silver RT, Macera MJ, Verma RS: Characterization of chromosome 11 with a complex inversion and deletion in an AML (M2) using fluorescence in situ hybridization.  Acta Haematol.  1995; 94:152-55.
  170. Henry DH, Brooks BJ Jr, Case DC Jr, Fishkin E, Jacobson R, Keller AM, Kugler J, Moore J, Silver RT, et al.  Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.  Cancer J Sci Am.  1995 Nov-Dec; 1(4):252-60.
  171. Coleman M, Silver RT:  Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia.  (England).  1995; 9(7):1116-20.
  172. Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, et al.  Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.  J Clin Oncol.  1996 May; 14(5):1589-98.
  173. Silver RT: Interferon Alpha:  Effects of Long-Term Treatment for Polycythemia Vera.  Seminars in Hematology.  1997; 34 (1); 40-50.
  174. Stock W, Westbrook CA, Bercedis P, Arthur DC, Szatrowski TP, Silver RT, et al:  Value of Molecular Monitoring During the Treatment of Chronic Myeloid Leukemia: A Cancer and Leukemia Group B Study.  J Clin Oncol.  1997; 15(1)26-36.
  175. Kornblith AB, Herndon II JE, Zuckerman E, Cella DF, Cherin E, Wolchok S, Weiss RB, Diehl LF, Henderson E, Cooper MR, Schiffer C, Canellos GP, Mayer RJ, Silver RT, Schilling A, Peterson BA, Greenberg D & Holland JC for the Cancer and Leukemia Group B: Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors.  Ann of Oncol.  1998; 9:297-306.
  176. Dewald GW, Wyatt A, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, Spurbeck JL, Silver RT:  Highly Sensitive Fluorescence In Situ Hybridization Method to Detect Double BCR/ABL Fusion and Monitor Response to Therapy in Chronic Myeloid Leukemia. Blood.  1998; 91:(9)3357-65.
  177. Buño I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald G:  A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia. Blood.  1998; 92(7):2315-21.
  178. Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, Van Genderen PJJ, Briere J, Barbui T, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, et al: Diagnosis, Pathogenesis and Treatment of the Myeloproliferative Disorders Essential Thrombocythemia, Polycythemia Vera and Idiopathic Myelofibrosis. (Proceedings of the Rotterdam MPD-Workshop March 13-14, 1998) (EWG.MPD) The Netherlands Journal of Medicine. 1999; 54:46-62.
  179. Silver RT: Chronic Myeloid Leukemia: Practice Guidelines, Trends in Onco-Hematology (selected reports from the 40th annual meeting of the American Society of Hematology) 1998 Dec; 6(4):60.
  180. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR: Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S: An Evidenced-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia:  Developed for the American Society of Hematology.  Blood.  1999; 94 (5):1517-36.
  181. DeWald GW, Wyatt WA, Silver RT: Atypical BCR and ABL D-Fish Patterns in Chronic Myeloid Leukemia & their Possible Role in Therapy.  Leukemia & Lymphoma.  1999; 34(5)481-91.
  182. Budd GT, Atiba J, Silver RT, Palmer G, Armstrong S, Otto K, Presant C.  Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer.  J Cancer Res Clin Oncol.  1999 Aug-Sep; 125(8-9):500-4.
  183. Engelhardt M, Mackenzie K, Drulinsky P, Silver RT, Moore MA: Telomerase Activity and Telomere Length in Acute and Chronic Leukemia, Pre- and Post-ex Vivo Culture. Cancer Res.  2000 Feb 1; 60(3):610-7.
  184. Michaels JJ, Barbui T, Finazzi G, Fuchtman SM, Kutti J, Rain JD, Silver RT, Tefferi A and Thiele J:  Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG.  Leukemia and Lymphoma.  2000; 36:239.
  185. Hensley ML, Pederson B, Silver RT, Larson RA, Schiffer CA and Szatrowski TP.  Risk Factors for Severe Neuropsychiatric Toxicity in Patients Receiving Interferon Alfa-2b and Low-Dose Cytarabine for Chronic Myelogenous Leukemia: Analysis of Cancer and Leukemia Group B 9013.  J Clin Oncol.  2000; 18:1301-08.
  186. Cameron CL, Cella D, Herndon JE, Kornblith A, Zuckerman E, Henderson E, Weiss RB, Cooper MR, Silver RT, Leone L, Canellos GP, Peterson BA, Holland JC.   Persistent symptoms among Survivors of Hodgkin’s Disease: An Explanatory Model Based on Classical conditioning.”  Health Psychology. MS#98-187R1. 2001; 20(1):71-5.
  187. Sirulink A, Silver RT, Najfeld V.  Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI-571.  Leukemia.  2001; 15(11):1795-7.  No abstract available.
  188. Talpaz M, Silver RT, Druker BJ, et al: Imatinib Induces Durable Hematologic & Cytogenetic Responses in Patients with Accelerated Phase Chronic Myeloid Leukemia: Results of a Phase 2 Study.  Blood.  2002; 99:1928-37.
  189. Roboz GJ, Bayer RL, Silver RT, et al: Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid Leukemia. Leukemia & Lymphoma.  2002; 43:1-5.
  190. Silver RT, Treatment of Polycythemia Vera with Recombinant Interferon. Int J Hematol.  2002; 76 Suppl 2:294-5.
  191. Lesser ML, DeWald GW, Silver RT, et al: Correlation of Three Methods of Measuring Cytogenetic Response in Chronic Myelocytic Leukemia.  Cancer Genetics and Cytogenetics.  2002; 137:(2)79-84.
  192. Ottmann OG, Druker BJ, Silver RT, et al: A Phase 2 Study of Imatinib in Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoid Leukemias.  Blood.  2002; 100:(6)1965-71. 
  193. Silver, RT, Peterson BL, Szatrowski TP, et al:  Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013.  Leukemia & Lymphoma.  2003; 44 (1):39-48.
  194. Strife, A, Wisniewski, D, Silver RT, et al: Direct Evidence That Bcr-Abl Tyrosine Kinase Activity Disrupts Normal Synergistic Interactions Between Kit Ligand and Cytokines in Primary Primitive Progenitor Cells.  Molecular Cancer Research.  2003; 1,(3):176-85.
  195. O’Brien, Guihot F, Silver RT, et al: Imatinib Compared with Interferon and Low Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New Engl J Med.  2003; 348(11):994-1004.
  196. Silver RT: A Hope For The Future.  Cancer Invest.  2003; 21(3):486.
  197. Silver RT: Imatinib Mesylate (Gleevec TM) Reduces Phlebotomy Requirements in Polycythemia Vera. Leukemia. 2003; 17:1186-7.
  198. Silver RT: Chronic Myeloid Leukemia.  Hematology/Oncology Clinics of North America.  2003; 17:1159-73.
  199. Feldman E, Najfeld V, Silver RT, et al: The emergence of Ph-, trisomy –8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.  Exp Hematol.  2003; 31(8):702-7.
  200. Michallet M, Maloisel F, Silver RT, et al: Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.  Leukemia.  2004; 18(2):309-15.
  201. Silver RT: Myelofibrosis: Thalidomide Finds a New Disease.  Mayo Clinic Proceedings.  2004 Jul; 79(7):857-8.
  202. Farag SS, Ruppert AS, Silver, et al: Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.  Int J Oncol.  2004; Jul 25(1):143-51.
  203.  Spivak JL, Silver RT: Imatinib mesylate in polycythemia vera.  Blood.  2004; 103(8):3241.
  204. Silver RT, Bennett JM, Deininger M, et al: Meeting Report: The Second International Congress On Myeloproliferative and Myelodysplastic Syndromes.  Leukemia Research.  2004 Sep; 28(9):979-85.
  205. Peerschke EI, Silver RT, Weksler B, et al.  Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists.  Br J Haematol.  2004 Oct; 127(2):195-203.
  206. Silver RT: Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.  Leukemia.  2004; 19(1):39-43.
  207. Silver RT: Current treatment of myelofibrosis.  Current Advances in Hematology & Oncology.  2005; (4):269-70.
  208.  Silver RT: Treatment of polycythemia vera with recombinant interferon α (rIFNα) or imatinib mesylate.  Current Hematology Rep.  2005; 4(3):235-37.
  209. Jones VJ, Kreil S, Zoi K, Silver RT, Reiter A, Cross CP, et al.  Widespread occurrence of the JAK2V617F mutation in chronic myeloproliferative disorders.  Blood.  2005; 106:2162-88.
  210. Silver RT. The ABCs of myelofibrosis.  Blood.  2005; 106:2598-99.
  211. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.  Blood.  2006 Apr; 107(8):3339-41. 
  212. Silver RT.  Treatment of Polycythemia Vera.  Semins Thromb Hemost.  2006 Jun; 32(4):437-42.
  213. Baccarani M, Saglio G, Goldman J, Silver RT, et al.  Evolving concepts in the management of chronic myeloid leukemia.  Recommendations from an expert panel on behalf of the European LeukemiaNet.  Blood.  2006; 108:1809-20.
  214. Silver, RT: Long-term effects of the treatment of polycythemia vera (PV) with recombinant interferon-alpha (rIFNa).  Cancer.  2006 Aug 1;107(3):451-8.
  215. Shore T, Silver RT, et al.  A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.  Biol Blood Marrow Transplant.  2006 Aug; 12(8):868-75. 
  216. Spivak JL, Moliterno AR, Silver RT.  Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.  N Engl J Med.  2006 Aug 17; 355(7):737-8.
  217. Silver, R.T.  The Budd-Chiari Syndrome and V617 Mutation in JAK2.  New Engl J Med.  2006; 355(7):737; author reply 738.
  218. Tefferi A, Mesa R, Silver RT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia: On behalf of the IWG for Myelofibrosis Research and Treatment (IWG-MRT).  Blood.  2006;108(5):1497-503.
  219. Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, Chen Y, Verstovsek S, Wang H, Prchal J, Yang XF.  An unconventional antigen translated by a novel internal ribosome entry site elicits anti-tumor humoral immune reactions in a subset of patients with Polycythemia vera.  Journal of Immunology.  2006; 177:4907-16.  
  220. Verstovsek S, Silver RT, Cross NCP, Tefferi A.  JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?  Leukemia.  2006; 20(11):2067.
  221. Bumm TGP, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Drucker BJ, Deininger MW.  Characterization of murine JAK2V617F positive myeloproliferative disease.  Cancer Res.  2006; 66(23):1156-65.
  222. Drucker BJ, Guilhot F, O’Brien SG, Gathmann M, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, et al.  Five-year follow-up of Imatinib therapy for newly diagnosed chronic myeloid leukemia in chronic-phase shows sustained responses and high overall survival.  N Engl J Med.  2006; 355(23):2408-17.
  223. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Silver RT, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-2417
  224. Silver RT, Bennett JM, Deininger M, et al.  The third international congress on myeloproliferative and myelodysplastic syndromes.  Leuk Res. 2007; 31(1):11-7.
  225. Xiong Z, Yan Y, Lieu E, Silver RT, Verstoversek S, Yang F, Wang H, Prchal J, Yang XF.  Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.  Clin Immunol.  2007; 122:279-87.
  226. Hochhaus A, Kantarjian H, Baccarani M, Lipton J, Apperley J, Druker B, Facon T, Goldberg S, Cervantes F, Niederweisser D, Silver RT et al.  Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy.  Blood.  2007; 109(6):2303-9.
  227. Peerschke EI, Silver RT, Weksler BB, Yin W, Bernhardt B, Varon D.  Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis.  Am J Clin Pathol.  2007; 127(3):422-8.
  228. Chen Q, Lu P, Jones AV, Cross NCP, Silver RT, Wang YL.  Amplification refractory mutation system (ARMS), a highly sensitive and simple PCR assay for the detection of JAK2V617F mutation in chronic myeloproliferative disorders.  J Molecular Diagnostics.  2007; 9(2):272-6.
  229. Silver RT.  Update on the Treatment of Polycythemia Vera with Recombinant Interferon Alfa or Imatinib Mesylate.  Current Hematologic Malignancy Rep.  2007; 2:43-46.
  230. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM.  Chronic Myeloid Leukemia – some topical issues.  Leukemia. 2007; 1(7):1347-52
  231. Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, Hodge I, Verstovsek S, Segura FJ, Wang H, Prchal J, Yang X-F.  A Novel Unconventional Antigen MPD5 Elicits Anti-Tumor Immune Responses in Subset of Patients with Polycythemia Vera.  International Journal of Immunopathology and Pharmacology.  2007; 2:373 - 375.
  232. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737-40. Epub 2007.  
  233. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia. 2007;21(7):1347-52. Epub 2007.
  234. Wang YL, Vandris K, Jones A, Cross NC, Christos P, Adriano F, Silver RT. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia. 2008;22(6):1289. Epub 2007.
  235. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200-6. Epub 2008.
  236. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204-12. Epub 2008.
  237. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231-9. Epub 2008.  
  238. Silver RT. Polycythemia vera and other polycythemia syndromes. Cancer Treat Res. 2008;142:1-27.
  239. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F and Cross NC.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.  Nat Genet. 2009; 41(4) 446-449.
  240. Silver RT, Cortes J, Waltzman R, Mone M, and Kantarjian H.: Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia long-term follow-up of the ST15710102 and 0109 trials.  Letter to the Editor. Haematologica. 2009; 94 (5): 743-744.
  241. Silver RT, Vandris K.: Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis.  Leukemia. 2009; 23 (7): 1366-9.
  242. Baccarani M, Cortes J, Pane F, Dietzger N, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonson B, Silver R, Goldman J and Hehlmann R.  Chronic Myeloid Leukemia:  An update of Concepts and Management Recommendations of European LeukemiaNet.  J Clin Oncol. 2009, 27 (35): 6041-6051.
  243. Silver R.  The Blast Phase of Chronic Myeloid Leukemia.  Best Practice & Research Clinical Hematology. 2009, (22): 387-394.
  244. Shah NP, Kim D-W, Kantarjian H, Rousselot P, Dorlhiac-Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Muller MC, Lambert A, Matloub Y, Hocchaus A.  Potent, transient inhibition of BCR-ABL with dasatinib 100mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.  Haematologica. 2010, 95(2): 232-240.
  245. Jones AV, Cambell P, Beer P, Schnittger S, Vannucchi A, Zoi K, Percy M, McMullin MF, Scott L, Tapper W, Silver RT, Oscier, Harrison Cn, Grailert H, Kisialiou A, Strike P, Chase AJ, Green A and Cross Nicholas CP.  The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010;(115) :4517-4523.
  246. Salie R, Silver RT.  Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2010; 10(5): 331-335.
  247. Najfield V, Tirpodi J, Scalise A, Silverman LR, Silver RT, Fruchtman S, Hoffman R.  Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukemia.  Br J Haematol. 2010, (3): 288-291.
  248. Tefferi A, Abdel-wahb O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian J-J, Levine RL, Licht JD, Mullaly A, Odenike T, Pardani A, Silver RT, Solary E, Mughal T. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th international post-American Society of Hematology Symposium, Blood Cancer Journal 2011, e7; doi:10.1038.
  249. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMul lin MF, Pardanani A, Passamonti F, Vannucchi A, Reiter A, Silver RT, Verstovsek S, and Tefferi A.  Philadelphia –Negative classical myeloproliferative neoplasms:  Critical concepts and management recommendations from European LeukemiaNet.  J Clin Oncol. 2011; 29(6):761-770.
  250. Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ and Cross NCP: JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.  Leuk Res. 2011; 35:(2), 177-182.
  251. Silver, RT:  Predictive Value of In Vitro Mutation Data to Guide Second-Generation Tyrosine Kinase Inhibitor Selection: Ready for Prime Time? Oncologist, 2011;16(5) 554-558.
  252. Spivak JL, Silver RT: How I treat essential thrombocythemia. Letter to the Editor.  Blood. 2011; 117(5):1472-82.
  253. Silver RT, Vandris K, and Goldman J:  Recombinant interferon alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood, 2011;117(24):6669-72.
  254. Hasselbalch HC, Kiladjian JJ, Silver RT:  Interferon alfa in the treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms.  J Clin Oncol. 2011; 29(18):564-565.
  255. Spivak JL, Silver RT:  The Treatment of essential thrombocytosis revisited.  Blood. 2011; 118(4): 1179-1180.
  256. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Silver RT, et al.: TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392-6398
  257. Silver RT, Bourla MH, Vandris K, Fruchtman S, Spivak JL, Feldman EJ, Salvado AJ.: Treatment of polycythemia vera with imatinib mesylate. Leuk Res. 2012; 36(2):156-62.
  258. Kuriakose E, Vandris K, Wang YL, Chow W, Jones AV, Christos P, Cross NC, Silver RT: Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.  Haematologica. 2012; 97(4):538-42.
  259. Santisakultarm TP, Cornelius NR, Nishimura N, Schafer AI, Silver RT, Doerschuk PC, et al: In vivo two-photon excited fluorescence microscopy reveals cardiac- and respiration-dependent pulsatile blood flow in cortical blood vessels in mice. Am J Physiol Heart Circ Physiol. 2012;302(7):H1367-77.
  260. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807.
  261. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013 6(1):49-58.
  262. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, et al: Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial.  J Clin Oncol. 2013; 31(10):1285-92.
  263. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM: The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013; 161(4):508-16.
  264. Kantarjian, Hagop, Silver, RT, et al: The Price of Drugs for Chronic Myeloid Leukemia (CML); A Reflection of the Unsustainable Prices of Cancer Drugs: From the Persepective of a Large Group of CMl Experts. Blood. 2013; 121(22):4439-42.
  265. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes FC, Clark RE, Cortes JE, Guilhot F, Hansen HH, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FZ, Martinell G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver RT, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R: European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia, Blood 2013 122(6):872-84.
  266. Mesa RA, Silver R, Verstovsek S, Mascarenhas J, Kessler C, Rondelli D, Goldberg J, Marchioli R, Demakos E, Silverman L, Hoffman R.: Single agent Bevacizumab for myelofibrosis: results of the Myeloproliferative disorders-Research Consortium Trial. Haematol. 2013 doi:10.3324.
  267. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ: Evaluation of WHO Criteria for Diagnosis of Polycythemia Vera: A Prospective Analysis. Blood. 2013 122(11):1881-6.
  268. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM.: Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013. 98(12):1865-71.
  269. Kuriakose ET, Gjoni S, Wang YL, Baumann R, Jones AV, Cross NCP, Silver RT: JAK2V617F allele burden is reduced by busulfan therapy: A new observation using an old drug. Hematol. 2013. 98(11):e135-7.
  270. Silver RT: All Interferons the Same for Therapy in Polycythemia Vera (PV)?. Clin Lymphoma Myeloma Leuk. 2013 Suppl 2:S305-6. doi: 10.1016/j.clml.2013.05.016.
  271. Kuriakose ET, Lascu E, Wang YL, Gjoni S, Cross NCP, Baumann R, Tam K, Scherk E, Longman RS, Silver RT: The JAK2V617F Mutation Seen in Myeloproliferative Neoplasms (MPNs) Occurs in Patients with Inflammatory Bowel Disease: Implications of a Pilot Study. Int J Clin Med. 2013. 4: 10-15.
  272. Kantarjian HM, Silver RT, Komrokji RS, Mesa RA Tacke R, Harrison CN: Ruxolitinib for Myelofibrosis – An Update of Its Clinical. Clin Lymphoma Myeloma Leuk. 2013;13(6): 638-45.
  273. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib JR, Gisslinger H, Levy RS, Siulnik A, Gupta V, Khan M, Dipersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014;99(2):292-8.

 

 

Honors and Awards

·     

  1. New York State Scholarship for Professional Study of Medicine, 1950-1953
  2. Visiting Fulbright Lecturer, University of Bahia School of Medicine, Brazil, 1958‑1959
  3. Big Pi Award for Outstanding Civic Achievement, 1975
  4. Cornell University Medical College Award of Appreciation, 1976
  5. New York State Society of Medical Oncologists and Hematologists Award of Appreciation for Service as President 1991-2000
  6. Richard T. Silver Distinguished Visiting Professorship,1998
  7. Pasmantier Award of the New York Cancer Society and Fund for Blood and Cancer Research for Outstanding Accomplishment and Distinguished Service to Clinical Medicine and Medical Oncology, June 1999
  8. Richard T. Silver Distinguished Professorship in Hematology & Medical Oncology at Weill Medical College of Cornell University, 2001
  9. Timothy Gee Award for Outstanding Clinician, Teacher, Mentor, Humanist presented by Sass & Strauss Foundation, May 19, 2001
  10. Lifetime achievement award for pioneering work in clinical hematology and as Founder and Medical Director of the Cancer Research & Treatment Fund (CR&T), 2008
  11. Distinguished Emeritus member, American Society of Hematology, 2010
  12. Lifetime of Academic Achievement, Dedication and Service to Weill Cornell Medical College (WCMC), 2011
  13. The Weill Cornell Medical College Alumni Association Special Achievement Award, 2012
  14. Lifetime Achievement Award, The SASS Foundation for Medical Research, Inc., 2012
  15. Lifetime Achievement Award in the field of Hematology, Israel Society of Hematology and Blood Transfusion and the University of Texas MD Anderson Cancer Center, 2013
  16. Dedication, Richard T. Silver, M.D. Myeloproliferative Neoplasm Center at Weill Cornell Medical College, New York, New York, Weill Cornell Medical College, 2014